Pharmaceuticals & Biotechnology - Fine Chemicals / Active Pharmaceutical Ingredients
Strategic Profile
Hikal is engaged in the business of pharmaceuticals, crop protection, and specialty chemicals. Strategic shifts towards enhancing its CDMO services and diversifying into personal care and specialty chemicals are expected to drive future growth. However, the company is currently facing headwinds with recent regulatory challenges and declining profitability.
Cyborg Score Rationale
The company reported consolidated net loss of Rs 22.40 crore in Q1 FY26 as against net profit of Rs 5.10 crore reported in Q1 FY25. The company has delivered a poor sales growth of 4.29% over past five years and a low return on equity of 6.81% over last 3 years. Recent FDA regulatory issues add execution risk.
Top Insights
Consolidated revenue of Rs. 380 crores for Q1 FY26, reflecting a decline from the previous year primarily due to deferred shipments in its Pharmaceutical division.
Share transfer for amalgamation executed; scheme sanctioned Nov 18, 2025, effective Dec 1, 2025, with former promoter-group shares moved to Castilia Life Sciences.
US FDA inspection at Jigani unit (Feb 2025) concluded with six observations; company confirmed it would address each observation and submit response within stipulated timeframe.
61.7% of the company's total energy requirement was met from renewable sources in the fiscal year.
Named Competitors
Torrent Pharmaceuticals — Integrated pharmaceutical company with stronger recent market performance
Sinochem Corporation — Strategic investor and chemical manufacturing competitor
Novartis — Former agrochemical manufacturing facility provider
Recent Developments
(February 2026) Castilia Life Sciences converted to LLP with 24.52% HIKAL shareholding vested
(February 2025) US FDA inspection at Jigani facility concluded with six observations requiring remediation
(May 2025) FDA inspection outcome classified as Official Action Indicated (OAI) for Jigani unit
Open the full interactive Hikal Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.